The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma
Diana Berry(McGill University), Ian R. Watson(McGill University Health Centre), Béatrice Wang, Simon Turcotte(Centre Hospitalier de l’Université de Montréal), Dan Moldoveanu(McGill University Health Centre), Tiffany Lin(McGill University), Réjean Lapointe(Montreal Neurological Institute and Hospital), Kevin Petrecca(McGill University Health Centre), Sarkis Meterissian(McGill University), T. Martin Schmeing(McGill University), Mathieu Lajoie(McGill University Health Centre), Itai Sharon(McGill University), Anne‐Marie Mes‐Masson(Centre Hospitalier de l’Université de Montréal), Shivshankari Rajkumar(McGill University Health Centre), Françis Rodier(Institute for Research in Immunology and Cancer), Daméhan Tchelougou(Centre Hospitalier de l’Université de Montréal), John Stagg(Institute for Research in Immunology and Cancer), Wilson H. Miller(Jewish General Hospital), Kevin Watters(McGill University Health Centre), Catalin Mihalcioiu(McGill University Health Centre), Antoine Bernard(Inserm), Keith Richardson(McGill University Health Centre), Sandy Pelletier(Centre Hospitalier de l’Université de Montréal), May Chergui(McGill University Health Centre), Rahima Jamal(Centre Hospitalier de l’Université de Montréal), Marie‐Christine Guiot(McGill University), Alan Spatz(Jewish General Hospital), Yael Ripstein(University of Manitoba), Ari N. Meguerditchian
Cited by 7
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA
|Developmental Cell|2014|2k
Four faces of cellular senescence
|The Journal of Cell Biology|2011|2k
A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future
|Current Oncology|2020|941